| Identification | Back Directory | [Name]
INDEX NAME NOT YET ASSIGNED | [CAS]
2684216-48-4 | [Synonyms]
4-[[(2S)-2-[[(2S)-2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]-3-methyl-butanoyl]amino]-5-ureido-pentanoyl]amino]phenyl]methyl N-[(1S)-1-[[(1S)-1-[[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenyl-ethyl]amino]-1-methoxy-2-methyl-3-oxo-propyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxo-butyl]-methyl-carbamoyl]-2-methyl-propyl]carbamoyl]-2-methyl-propyl]-N-methyl-carbamate | [Molecular Formula]
C64H103N13O15 | [Molecular Weight]
1294.58 |
| Chemical Properties | Back Directory | [Boiling point ]
1419.3±65.0 °C(Predicted) | [density ]
1.205±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
13.29±0.46(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Biological Activity]
Gly3-VC-PAB-MMAE consists a cleavable ADC linker (Gly3-VC-PAB) and a potent tubulin inhibitor (MMAE). Gly3-VC-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs)[1].
ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[1]. | [References]
[1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337. |
|
|